Adamis Pharmaceuticals: Trying To Find A Course Of Action [Seeking Alpha]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Seeking Alpha
SummaryAdamis Pharmaceuticals reported weak Q4/2019 earnings with a miss on EPS and revenue. The company revealed disappointing fourth-quarter numbers for Symjepi. Unfortunately, the company decided to forgo a conference call.I review some of the company's past and ongoing blunders in order to forge a new thesis.I believe the company needs to reassess their strategy and consider a reorganization in order to regain the market's trust. I discuss my top three scenarios.Adamis Pharmaceuticals (ADMPSymjepi FlopsThe company's flagship product, Symjepi, was the primary motivation for starting a position in ADMP. Symjepi was supposed to be a competition for Mylan's (MYLNVSstatedI am not sure what Adamis is really expecting Sandoz to do… I was impressed with their ability to get favorable positions on the formularies, but, I haven't seen any serious attempts at digital marketing for the product. Sadly, most of my Symjepi web searches bring me to my previous articles. I don't expect Sandoz to
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Novartis (NYSE:NVS) had its "buy (b)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Novartis (NYSE:NVS) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.MarketBeat
- Janux dives as gaps in prostate cancer study data worry investors [Yahoo! Finance Canada]Yahoo! Finance Canada
- Progress In Fight Against Malaria, As New Treatment Shows Promise [Forbes]Forbes
- Novartis (NYSE:NVS) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=NVS&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from MarketBeat
NVS
Earnings
- 10/28/25 - Miss
NVS
Sec Filings
- 11/25/25 - Form 6-K
- 11/20/25 - Form 6-K
- 11/5/25 - Form 6-K
- NVS's page on the SEC website